RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: 15
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGACGCGUACGCAAGUACUGUGAUACAG3'
Sequence length: 33
GC content: 0.4848484848484848
Affinity: Kd: 4.1*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 17
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGACGCGCUGGUACGCAAGUACGGCUGUGAUACAG3'
Sequence length: 40
GC content: 0.55
Affinity: Kd: 3.9*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 20
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUACUCUCGUACGCAAGUACGAUCGAGACACAG3'
Sequence length: 38
GC content: 0.4736842105263157
Affinity: Kd: 2.6*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 51
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUGAGCUCGUACGCAAGUACUCGAGGUACAG3'
Sequence length: 36
GC content: 0.5
Affinity: Kd: 1.0*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 58
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUACUCCUGUACGCAAGUACGGUUGAGACACAG3'
Sequence length: 38
GC content: 0.4736842105263157
Affinity: Kd: 3.2*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 72
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUAUGAGAGUAGCAAGUACCGGACUCUACAG3'
Sequence length: 36
GC content: 0.4444444444444444
Affinity: Kd: 0.3*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 73
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUGCUCGUGUACGCAAGUACGCUUGAGGAACAG3'
Sequence length: 38
GC content: 0.5
Affinity: Kd: 1.4*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 86
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUGUAGAGGUACGCAAGUACGCGCUCCACAG3'
Sequence length: 36
GC content: 0.5277777777777778
Affinity: Kd: 6.4, 6.5, 7.4, 9.7*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 92
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUGUAGAGGUACGCAAGUAAGCGGCUCCACAG3'
Sequence length: 37
GC content: 0.5135135135135135
Affinity: Kd: 7.4*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 22
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGUACGUUGUACGCAAGUACACGGGUUACAG3'
Sequence length: 36
GC content: 0.4722222222222222
Affinity: Kd: 0.7*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 59
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGCUUCGUACGCAAGUAUGAUGAUACAG3'
Sequence length: 33
GC content: 0.4242424242424242
Affinity: Kd: 0.2*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 61
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGACAUCGUACGCAAGUACCUUGAAACAG3'
Sequence length: 34
GC content: 0.4411764705882353
Affinity: Kd: 4.6*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 76
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGACUUCGGUACGCAAUUACCGACUGACACAG3'
Sequence length: 37
GC content: 0.4864864864864865
Affinity: Kd: 2.4*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 79
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGGACAUUUGUACGCAAGUACGUUUGAUACAG3'
Sequence length: 36
GC content: 0.3888888888888889
Affinity: Kd: 3.9*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 18
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCGGUAGCAUCUUGUACGCAAGUACGAGAGAGCAACAG3'
Sequence length: 40
GC content: 0.475
Affinity: Kd: 0.5*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 16
Target: α-Thrombin, Human
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAUGCCUGUCGAGCAUGCUGCAUCCGGAUCGAAGUUAGUAGGCGGAGUGGUAGCUAAACAGCUUUGUCGACGGG3'
Sequence length: 78
GC content: 0.5641025641025641
Affinity: Kd: 37 ± 3.5 nM
Pool type: 5'-CCCGTCGACAAAGCTGTTTAGCTAC-N30-CAGCATGCTCGACAGGCATCT-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl, pH 7.7, 100 mM NaCl, 1 mM DTT, and 1 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.7
Molecular weight of target: Not reported
Post-SELEX modifications: Minimum sequence requirements for high affinity binding derived from clone 16 (truncated)
Application as quoted in the referenced paper: Therapeutic: " These sequences can be used as a molecular anchor to select for a larger RNA with more extensive protein interactions, including the active site. One can also envision development of a heparin mimic that could be more specific for the ATIE-mediated inhibition of thrombin. It is clear from this work and related work that oligonucleotides have great potential as antithrombotic agents."
Additional information: 5' and 3' fixed regions differ than pool non-random regions.
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.

Reference (1994, Nucleic Acids Res ): Kubik, M. F., Stephens, A. W., Schneider, D., Marlar, R. A., & Tasset, D. (1994). High-affinity RNA ligands to human alpha-thrombin. Nucleic acids research, 22(13), 2619–2626. https://doi.org/10.1093/nar/22.13.2619